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thetic joint infections (PJIs). METHODS: A retrospective analysis of consecutive streptococcal PJIs was
performed. Musculoskeletal Infection Society 2013 criteria were used. Outcome was compared with a
prospective PJI cohort from the same institution. RESULTS: The most common isolated streptococ-
cal species was Streptococcus dysgalactiae (9/22, 41%) among 22 patients included. Surgical treatment
consisted of DAIR (debridement, antibiotics, irrigation and retention) in 12 (55%), one-stage revision
arthroplasty in one (4%), two-stage revision arthroplasty in eight (37%) and implant removal in one (4%)
patient. An infection free-outcome was achieved in 15 cases (68%), whilst seven (32%) patients failed
initial revision and relapsed with the same pathogen, from which six were treated with DAIR and one
with one-stage revision arthroplasty. No failures were observed in patients who received a two-stage
revision. Failure rates did not differ in the cases treated with rifampin (1/5) from those without 6/17 (p
= 0.55). There was no correlation between the length of antibiotic treatment and relapse (p = 0.723). In
all failures, a persistent distant infection focus was identified at the time of relapse. Compared with our
prospective PJI cohort, relapse rates were significantly higher 32% vs 12% (p < 0.05). CONCLUSION:
No correlation with the use of rifampin or length of antibiotic treatment was found. No failures were
observed in patients who received a two-stage revision, which may be the surgical treatment of choice. A
distant persisting infection focus could be the reason for PJI relapse with recurrent hematogenous seeding
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Abstract
Purpose To report and analyse factors affecting the outcome of streptococcal periprosthetic joint infections (PJIs).
Methods A retrospective analysis of consecutive streptococcal PJIs was performed. Musculoskeletal Infection Society 2013
criteria were used. Outcome was compared with a prospective PJI cohort from the same institution.
Results The most common isolated streptococcal species was Streptococcus dysgalactiae (9/22, 41%) among 22 patients in-
cluded. Surgical treatment consisted of DAIR (debridement, antibiotics, irrigation and retention) in 12 (55%), one-stage revision
arthroplasty in one (4%), two-stage revision arthroplasty in eight (37%) and implant removal in one (4%) patient. An infection
free-outcome was achieved in 15 cases (68%), whilst seven (32%) patients failed initial revision and relapsed with the same
pathogen, from which six were treated with DAIR and one with one-stage revision arthroplasty. No failures were observed in
patients who received a two-stage revision. Failure rates did not differ in the cases treated with rifampin (1/5) from those without
6/17 (p = 0.55). There was no correlation between the length of antibiotic treatment and relapse (p = 0.723). In all failures, a
persistent distant infection focus was identified at the time of relapse. Compared with our prospective PJI cohort, relapse rates
were significantly higher 32% vs 12% (p < 0.05).
Conclusion No correlation with the use of rifampin or length of antibiotic treatment was found. No failures were observed in
patients who received a two-stage revision, which may be the surgical treatment of choice. A distant persisting infection focus
could be the reason for PJI relapse with recurrent hematogenous seeding in the joint.
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Introduction
Periprosthetic joint infections (PJIs) pose a significant prob-
lem in orthopaedics due to increased morbidity and mortality
[1–3]. Streptococci are the second leading cause of infections
and account for about 10% of PJIs [4] (incidence varies be-
tween 4 and 16% among reports) [5, 6]. Streptococcal infec-
tions were thought to be easy to treat due to their broad anti-
microbial sensitivity (including penicillin), but the success
rates of treatment are contradictory, and all seem to be inferior
due to high relapse infection rates (38–46%) [6, 7]. This is
thought to occur because of the ability of biofilm production.
There is also currently no consensus regarding the role of
rifampin addition in streptococcal biofilm infections, as stud-
ies reveal controversial findings [6, 8].
A recent prospective study reported statistically significant
improvement in successfully treated patients that received
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long-term antimicrobial therapy for at least six months [9]. As
such, treatment protocols for streptococcal PJI are heteroge-
neous and include different surgical strategies, different selec-
tion as well as dosage and duration of antibiotic treatment.
As there is no consensus on the influence of surgical treat-
ment selection, the role of rifampin addition, as well as the
length and type of antibiotic treatment, it was the purpose of
this retrospective study to look for any possible associated risk
factors in streptococcal PJI treatment failures.
Patients and methods
A retrospective study using the institutional microbiology da-
tabases for streptococcal PJIs between February 2011 and
February 2019 was performed. Patients were consecutively
identified, and data were obtained by extracting the electronic
medical records of patients with streptococcal PJI. An ethical
approval was obtained, and all patients signed a written in-
formed consent form. The study was carried out in accordance
with the World Medical Association Declaration of Helsinki
[10].
PJI was defined as a positive diagnosis based on the pres-
ence of either 1 major criterion or 3/5 of the minor criteria,
according to the MSIS (Musculoskeletal Infection Society)
guidelines [11]. Major criteria were considered the following:
sinus tract communicating with prosthesis or pathogen isolat-
ed by culture from two separate tissue/fluid samples from the
affected joint. Minor criteria consisted of the following: ele-
vated ESR (> 30 mm/h) or CRP (> 10 mg/L), elevated syno-
vialWBC (> 3000 cells/μL), elevated synovial PMN (> 80%),
purulence in affected joint and pathogen isolation in one cul-
ture [11, 12].
Infections were further classified into early and late infec-
tions according to the time of PJI onset following last surgical
revision: less than three months for early and more than three
months for late infections, respectively. In addition, the type
of presentation acute (symptoms < three weeks after index
surgery) or chronic, as well as the presumed source of infec-
tion, was noted. Haematogenous PJI was defined by diagnosis
of infection ≥ one month after surgery, acute manifestation
after a pain-free period and positive blood cultures or surgical
prosthetic site culture and/or evidence of distant infectious
focus consistent with the pathogen [5].
Success of treatment was defined as an infection-free out-
come which fo l lowed the Delph i In te rna t iona l
Multidisciplinary Consensus guidelines [13]: well-healed scar
with no clinical signs of recurrent or new infection, no further
revisions for septic reasons after re-implantation, no PJI-
related death and no long-term antimicrobial suppression ther-
apy at least 12 months after surgery [13]. Antibiotic suppres-
sive treatment was defined as continued antibiotic treatment of
longer than six months post-operatively.
Extracted data was then compared with the results of the
prospective PJI cohort from the same institution, which was
started in 2018 and included consecutive periprosthetic joint
infections with all types of pathogens. The comparison was
performed in order to underline the significant differences in
the outcome and failure rates between periprosthetic joint in-
fections from a consecutive cohort from the general popula-
tion and PJIs with streptococcal pathogens only.
For statistical analysis, SPSS Statistics 24.0 software (IBM,
Armonk, NY, USA) was used. Student’s t test was used to
determine any statistical differences between comparable
means. The relative risk (RR) and odds ratios were used to
determine if independent factors were associated with specific
outcomes. A bivariate Pearson correlation model was used to
assess correlation.
The probability of infection-free survival and the respective
95% confidence interval (CI) was estimated using the Kaplan-
Meier survival method. For image creation and statistical sur-
vivorship analysis, GraphPad Prism V8 Software was used.
For all performed analysis, the α level was set at 0.05, and all
P values were 2-tailed.
Results
A total of 22 patients (13 males, 9 females) with streptococcal
PJIs were considered eligible and included in the study, in-
volving 11 hip, eight knee, two shoulder and one hand
arthroplasties. One patient had a follow-up of less than
12 months and was excluded from the study. Demographic
and clinical data including relevant comorbidities with strep-
tococcal PJI included in our study are summarized in Table 1.
The median patient age was 68 years (50 to 90) at time of
diagnosis, and the median follow-up was 15 months (range
12–83 months). Five PJIs (23%) were classified as early in-
fection (< 3 months after index surgery), and seventeen (77%)
were late infections (> 3 months). In seven patients (32%),
previous revision surgery had been performed. The presumed
route of infection was hematogenous in 21 cases, whilst one
was considered as intra-operative acquired at the time of the
last surgery of the involved joint. In eleven patients (50%), a
comorbidity that may increase the risk for infection could be
identified.
Microbiology
The most commonly isolated streptococcal spp. were the fol-
lowing: Streptococcus. dysgalactiae in 9/22 (40.9%) and
S. mitis in 7/22 (31.8%) of cases, followed by S. anginosus
in three cases. Positive blood cultures as a sign for
haematogenous infection were found in seven out of 13
(54%) infection. Antibiotic resistance to either levofloxacin
or clindamycin was found in two patients (Table 2).
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Treatment
Surgical treatment consisted of DAIR (debridement, antibi-
otics, irrigation and retention) in 12 (54.5%) patients, one-
stage revision arthroplasty in one (4.5%) patient, two-stage
revision arthroplasty in eight (36.5%) patients and implant
removal in one (4.5%) patient (Table 2). The median antibi-
otic treatment duration was 83 days (range 38–133) with a
median of 27 days for intravenous antibiotic administration
(range 4–54). Rifampin was used in five (22.7%) cases: in
two out of 11 patients treated with DAIR, in two out of eight
patients with two-stage arthroplasty and in the one patient
with one-stage exchange of the prosthesis. Antibiotic choice
was according to susceptibility testing of the isolated strepto-
coccal species.
Outcome
The survivorship defined as infection free-outcome was
achieved in 15 cases (68.1%), whilst seven (31.9%) patients
failed initial revision (Fig. 1) and relapsed with the same path-
ogen. Two out of seven patients relapsed whilst taking
Table 1 Characteristics of 22 patients with a streptococcal
periprosthetic joint infection
Patient characteristics Number (%) (n = 22)
Sex, male (%)/female (%) 9 (59)/13 (41)
Age years, median (range) 68 (range 50–90)
BMI (kg/m2), median (range) 28.4 (range 20–39.1)
Follow-up months, mean (range) 25.5 (range 12–83)
Relevant comorbidities 11 (50%)
Diabetes mellitus 4 (18%)
Illicit drug abuse 2 (9%)
Hepatitis C 2 (9%)
GI ulcer 2 (9%)
Psoriasis (active lesions) 2 (9%)
Cirrhosis 1 (4.5%)
Neoplasia (multiple myeloma) 1 (4.5%)
Previous neoplasia (osteosarcoma) 1 (4.5%)







With sinus tract 5 (23%)
Duration of symptoms until septic surgery
Acute (less than 3 weeks of symptoms) 20 (91%)
Chronic 2 (9%)
Time of presentation with suspected infection
Early (< 3 months from index surgery) 7 (32%)
Late (> 3 months from index surgery) 17 (77%)
Type of source of infection
a) Hematogenous 21 (95.5%)
b) Intra- or postoperative acquired 1 (4.5%)
Potential source of infection
Unknown 13 (59%)
Oral cavity 4 (18%)
Urinary tract infection (graft associated) 1 (4.5%)
IV drug usage 1 (4.5%)
Ipsilateral foot ulcer 1 (4.5%)
Open skin lesions (psoriasis) 1 (4.5%)
Intra- or postoperative acquired 1 (4.5%)
Surgical treatment
DAIR 12 (55%)
One-stage revision 1 (4.5%)
Two-stage revision 8 (36%)
Implant removal 1 (4.5%)
Antibiotic treatment
Combination with rifampin 5/22 (22.7%)
Total antibiotic duration, days (range) 82.2 (range 38–133)
Duration of intravenous antibiotics, days (range) 27.4 (range 4–54)
Suppressive antibiotic treatment (SAT)* 3 (13.6%)
Table 2 Microbiological findings of 22 streptococcal periprosthetic
joint infections (PJI) in our study, summarized after synovial and sonica-
tion fluid, tissue biopsies, as well as blood cultures
Streptococcal species N = 22 (100%)
S. dysgalactiae (group C Streptococcus) 9 (41%)
S. mitis/oralis 8 (36%)
S. anginosus 3 (14%)
S. agalactiae (group B Streptococcus) 1 (4.5%)
S. pneumoniae 1 (4.5%)
Blood cultures, obtained (%) N = 13 (59%)
Positive 7 (54%)
Negative 6 (46%)
Antimicrobial susceptibility N = 15 (68%)
Pansensitive (penicillin, clindamycin, levofloxacin) 13 (87%)
Levofloxacin Resistance * 1 (6.5%)
Erythromycin and/or clindamycin resistance** 2 (13%)
Nr number, UTI urinary tract infection, DAIR debridement, antibiotics,
irrigation and retention, n/a not available, SSI surgical site infection
*In one case with S. agalactiae
**In two cases, one S. agalactiae and one S. pneumoniae
PJI periprosthetic joint infection, UTI urinary tract infection, DM II dia-
betes mellitus type 2, GI gastrointestinal, DAIR debridement, antibiotics,
irrigation and retention
*SAT was defined as continued antibiotic treatment of longer than
6 months postoperatively
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antibiotics after DAIR: one at 30 days after PJI surgery and
one at 46 days. In six out of seven failures (86%), an initial
DAIR surgical treatment was done. One failure occurred after
a one-stage revision arthroplasty. No failures were observed in
patients who received a two-stage revision.
To treat the relapse, a patient underwent an implant remov-
al and was scheduled for reimplantation but instead remained
under suppression therapy due to continuous UTI graft–
associated infection. Another two patients underwent two-
stage revision arthroplasty and had positive outcomes. There
was one patient who relapsed for three consecutive times with
the same pathogen (S. dysgalactiae) after repeated two-stage
revision. He was suffering from ongoing untreated psoriasis
skin lesions, which may constitute a distant infectious focus.
He was placed on suppression therapy until dermatologic
clearance. Three other patients remained under suppression
antibiotic treatment due to incompliance in two (untreated
dental infection and continued illicit drug abuse), and one
patient was not operable (Table 3).
Failure rates did not statistically differ in the cases treated
with rifampin (1/5) from those without 6/17 (relative risk
(RR) = 0.56, p = 0.55). The Pearson correlation test did not
show any correlation between length of antibiotic treatment
and relapse risk (p = 0.723). One patient with a failure after
DAIR was treated for six weeks with antibiotics, a shorter
period as compared with other participants (Table 3). The
most common organism that was found in the failure group
was represented by S. dysgalactiae—5/7 (71.4%) of cases.
There was an increased risk for this pathogen to lead to a
relapse when compared with the rest of pathogens all together
(odds ratio = 8.12, p = 0.038).
In all failures, a persistent distant infection focus at time of
relapse was identified or suspected: one graft infection, two
active gastrointestinal ulcers, one with open skin lesions due
to psoriasis, one purulent dental infection, one patient with
continued drug abuse and repetitive skin infections and one
patient with persistent elevated inflammatory markers and no
signs of local infection.
Fig. 1 The dotted lines represent the 95% CI (confidence intervals). The
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When compared with the prospective PJI cohort from our
institution (n = 49) with a minimum follow-up of 12 months,
relapse rates in the streptococcal cohort were significantly
higher: 32% vs 12% (p<0.05) (Fig. 2). The main pathogens
from the prospective cohort included S. aureus in 8 (16.7%),
coagulase-negative staphylococci in 14 (29.2%), Streptococcus
spp. in six (12.5%), Cutibacterium spp. in four (8.3%) and
Gram-negative rods in four (8.3%) of patients (Fig. 2).
Discussion
Streptococcal PJIs should be easily be treatable because of
their acute presentation making a DAIR possible the good
susceptibility to most of our available antibiotics [14, 15].
As such, the streptococcal PJIs are currently not evaluated as
“difficult-to-treat” infections. However, there is increasing ev-
idence that these infections should be labeled as “difficult to
treat” due to high failure rates [6, 7]. The current study sup-
ports these studies, as the infection-free survivorship of treated
streptococcal PJI was much lower (68.1%) than in the consec-
utive prospective cohort from our institution (87.7%).
The role of antibiofilm antibiotics against streptococcal
biofilms is still poorly understood. There are reports that dem-
onstrated that group B streptococci are able to produce
biofilms [16, 17]. An in vitro study [18] demonstrated the
eradication of streptococcal biofilms necessitated (> 125-fold
higher) concentrations of all tested antibiotics as compared
with the eradication of planktonic bacteria [18]. A recent ret-
rospective study by Renz et al. [9] analysed different antibiotic
treatment regimens on the outcome of streptococcal
periprosthetic joint infections [9]. The addition of rifampin
was not associated with better outcome, which results in ac-
cordance with a previous published study from the same in-
stitution [6]. On the other hand, there are contradictory reports
stating that rifampin addition does achieve better results [7, 8].
In our study, no relationship between rifampin addition and
clinical outcome could be found. Further studies are therefore
warranted for clarification.
In terms of surgical treatment, previous reports did not
observe substantial differences between the types of septic
surgery [6–8]. Although there is evidence that DAIR should
be surgically sufficient for streptococcal PJIs [19], the recent
multicentre study by Lora Tamayo et al. [7] showed a worse
prognosis than previously reported in a series of 462 DAIRs.
In our cohort, we achieved clinical cure in all cases treated
with a two-stage revision arthroplasty. This finding is support-
ed by another recent study by Citak et al. [20], where strepto-
coccal isolation was identified as a risk factor for failure in
one-stage revision arthroplasty for PJI.
Previous studies were able to identify a distant infectious
focus only in a minority of cases [6, 21, 22], whilst all failures
in our study occurred in patients with a potential persistent
source of distant infection focus. As such, an active interdis-
ciplinary search to find the source of haematogenous infection
should be pursued in all patients to decrease the risk of relapse.
There are limitations of our study. First, the design is not a
matched case-control study and is retrospective, although a
comparison with a prospective PJI cohort was performed.
Second, our study number is low and we deal with a variety
of different cases regarding streptococcal species, infection
route, prosthesis type and surgical and antimicrobial treatments.
In conclusion, our data of 32% relapse rate supports the
need for treating streptococcal PJI as difficult to treat. We
did not find any significant correlation with the use of rifam-
pin or length of antibiotic treatment. The most common iso-
lated microorganism among failures was S. dysgalactiae.
However, no failures were observed in patients who received
a two-stage revision. A persistent distal infection focus was
often suspected in cases with treatment failure. An aggressive
Fig. 2 Final outcomes of
streptococcal PJIs (A) compared
with the prospective PJI cohort





Streptococcus species (6, 12.5%),
Enterococcus species (2, 4.2%),
Pseudomonas species (1, 2.1%),
Escherichia coli (0), other gram-
negative rods (4, 8.3%), anaer-
obes (1, 2.1%), Cutibacterium
species (4, 8.3%), fungi (1, 2.1%),
other monobacterial pathogens
(0), culture negative PJI (3, 6.3%)
and polymicrobial (4, 8.3%).
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surgical treatment together with appropriate identification and
treatment of a distant primary focus should improve outcomes
in treatment of streptococcal PJIs.
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